Yoshida H, et al. - The tolerability and efficacy of nedaplatin (NDP) between patients older and younger than 70 years of age with ovarian cancer (OC) are compared in this study. Although NDP is a helpful therapeutic alternative for OC, careful consideration of the adverse impact ought to be given for patients 70 years and older.

Methods

• In this study, they enlisted 56 patients with OC who were treated with NDP monotherapy and divided them into those who were 70 years and older (n = 18) and younger than 70 years (n = 38).
• In this study, NDP was administered intravenously until disease progression or unacceptable toxicities occurred.

Results

• The incidences of grade 3/4 hematological toxicities were significantly higher in the older patients than in the younger patients, including anemia (p = 0.0021), leucopenia (p = 0.029), neutropenia (p = 0.0048), and thrombocytopenia (p = 0.0024).
• The incidence of raised creatinine was also significantly higher in the older patients (p = 0.0063).
• Older patients had significantly more frequent dose reductions (p = 0.017) and treatment interruptions from toxicity (p = 0.04).
• The tumor response rate for NDP did not differ significantly between younger (29%) and older (28%) patients (p = 0.47).
• The two age groups also did not significantly differ in progression-free survival (p = 0.27) and overall survival (p = 0.46).